KYORIN Pharmaceutical (4569) · FactCited as achieved
Gain on Debt Forgiveness from Partial Waiver of Repayment Obligations on Long-Term Borrowings from JST
First written in FY2021-Q2. 1 of 2 entries say "Cited as achieved", first in FY2021-Q3. Latest entry: FY2021-Q3.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Recording of Gain on Debt ForgivenessA theme 18 companies write about · 0 as a headwind · 18 as a tailwind
2 other companies' latest entry also says "Cited as achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 18 companies compared. The sentences above are computed from all 18.Full recordFilings, disclosures and news, newest first
- FY2021-Q3Cited as achievedAnnual report
「This resulted from the forgiveness of repayment obligations on long-term borrowings from the Japan Science and Technology Agency.」
The gain on debt forgiveness of ¥1,073 million from the waiver of the obligation to repay long-term borrowings is restated as a factor contributing to extraordinary income. - FY2021-Q2First statedAnnual report
「This resulted from the forgiveness of repayment obligations on long-term borrowings from the Japan Science and Technology Agency.」
The partial forgiveness of repayment obligations on long-term borrowings resulted in a ¥1.073 billion gain on debt forgiveness recorded as extraordinary income.